Press Release

GBT Announces Participation in Upcoming Investor Conferences

Sep 03, 2020 at 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:

  • Wells Fargo Securities 2020 Healthcare Conference on September 9 at 3:20 p.m. ET;
     
  • H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 10:00 a.m. ET;
     
  • Morgan Stanley 18th Annual Global Healthcare Conference on September 16 at 10:15 a.m. ET; and
     
  • Cantor Fitzgerald Virtual Global Healthcare Conference on September 17 at 11:20 a.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcast will be archived and available for one month following each event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Stephanie Yao (investors)
650-741-7730
syao@gbt.com


GBT new logo.png

Source: Global Blood Therapeutics, Inc.